Session » Rheumatoid Arthritis – Human Etiology and Pathogenesis II

Date: Wednesday, November 8, 2017

Time: 9:00AM-10:30AM

Meeting: 2017 ACR/ARHP Annual Meeting

Abstract Number: 2914

Anti-CCP Antibody Levels Are Elevated in Cervicovaginal Fluid in Association with Local Inflammation in Premenopausal Women without RA

Abstract Number: 2915

Increased Expression of Malondialdehyde-Acetaldehyde Adducts (MAA) and Anti-Maa Antibody in Rheumatoid Arthritis-Interstitial Lung Disease

Abstract Number: 2916

The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients

Abstract Number: 2917

Neutrophil Activation in Rheumatoid Arthritis – Potential Biomarkers of Disease Activity and Severity

Abstract Number: 2918

The Appearance of IgA RF Followed By IgG RF Is Associated with Transition to Classifiable RA in a Large Preclinical RA Cohort

Abstract Number: 2919

Number and Type of ACPA Fine Specificities Are Correlated to High Resolution Computed Tomography Parenchymal Lungs Changes in Patients with Early Untreated Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.